Home-based monitoring of muscle strength in patients with ALS
Completed
- Conditions
- Amyotrophic Lateral Sclerosis10029317
- Registration Number
- NL-OMON50814
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Is diagnosed with ALS of PMA
Has a minimal muscle strength of MRC 3 in at least one leg
Sufficient knowledge of the Dutch language to complete the questionnaires
Signed informed consent
Exclusion Criteria
Severe cognitive impairments
Current knee pain
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is the feasibility (expressed as acceptance and adherence<br /><br>to the 2-weekly assessment of muscle strength measurements using the PFD in the<br /><br>home-situation. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary outcome is the rate of decline in muscle strength during the<br /><br>follow-up period. The trajectory of independent muscle strength measurements<br /><br>over time will be compared with the Revised ALS Functional Rating Scale<br /><br>(ALSFRS-R).</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie muscle strength decline in ALS patients monitored at home in NL-OMON50814?
How does home-based muscle strength monitoring in NL-OMON50814 compare to standard clinical assessments for ALS progression tracking?
Are there specific biomarkers associated with ALS subtypes that could enhance the predictive value of home-based muscle strength monitoring in NL-OMON50814?
What are the potential adverse events of non-invasive home monitoring devices in ALS patients and how are they managed?
What combination therapies or devices are being explored alongside home-based monitoring to improve ALS patient outcomes?